ACVR1 (ALK2)
ACVR1 (ALK2) is the receptor that raises hepcidin, the hormone that hides iron from the bone marrow. Momelotinib and pacritinib block it as well as JAK2, which is why they improve, rather than worsen, the low red-cell counts of myelofibrosis. This dossier gathers the 2 products (2 approved), 2 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
In myelofibrosis the target is ACVR1 in the hepcidin pathway rather than in the malignant clone: the pacritinib record notes that sparing JAK1 while blocking JAK2, FLT3, IRAK1 and ACVR1 lets it be used with very low platelet counts, and the momelotinib record credits ACVR1 inhibition for its effect on anaemia.
- Hepcidin regulation (anaemia of myelofibrosis)
- Bone morphogenetic protein signalling in normal development
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →| Modality | Approved |
|---|---|
| Small molecule 2 |
Trials
Evidence ranking →| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
MOMENTUM NCT04173494 | 3 | Positive | Symptomatic, anaemic myelofibrosis previously treated with a JAK inhibitor: momelotinib against danazol | Momelotinib improved symptom response, transfusion independence and spleen response compared with danazol; approved in September 2023. | |
| 2 | Recruiting | A Randomized Phase 2 Study of Pacritinib vs. Hydroxyurea in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia | - |
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Ideas and companies
Literature
Preprints →Query for this target: (TITLE:"ACVR1" OR ABSTRACT:"ACVR1" OR TITLE:"ALK2" OR ABSTRACT:"ALK2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ACVR1 (ALK2), not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/acvr1.json. Licence CC BY-NC 4.0.